XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Xenon Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$35.08+1.59 (+4.75%)
Close on Oct 19, 2026
- Market cap
- $3.49B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-4974.3%−4877.0 pts over 5 years
Net margin
-4612.1%−4522.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | -7.4% | -25.3% | -7.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -36.8% | -21.9% | -51.8% | |
| Return on assets | -35.0% | -17.1% | -48.3% | |
| Current ratio | 18.31 | 12.30 | 13.42 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | -64.7× | – | |
| Capex to revenue | 15.5% | 8.2% | 10.7% | |
| Diluted shares | 15M | 35M | 79M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Xenon Pharmaceuticals generated $782.15M from operations and spent $14.44M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$782.15M
Used
$14.44M
Capital expenditure$14.44M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4612.1%
×Asset turnover0.01×
×Equity multiplier1.07×
=Return on equity, FY2025-51.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4612.1% | 0.01× | 1.07× | -51.8% |
| FY2022 | -1328.9% | 0.01× | 1.04× | -19.7% |
| FY2021 | -427.8% | 0.05× | 1.06× | -21.9% |
| FY2020 | -89.7% | 0.19× | 1.28× | -21.9% |
| FY2019 | -609.1% | 0.05× | 1.38× | -42.6% |
| FY2017 | -9872.7% | 0.01× | 1.14× | -61.5% |
| FY2016 | -1275.5% | 0.03× | 1.05× | -36.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$345.91M
- Cash generatingOperating cash flow above zero-$279.12M
- Return on assets improvedROA up on the prior year-24.3% → -43.3%
- Earnings backed by cashOperating cash flow above net income-$279.12M vs -$345.91M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose17.85 → 13.42
- No dilutionShare count did not rise78M → 79M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.01